Amber C Donahue
Overview
Explore the profile of Amber C Donahue including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
444
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Choueiri T, Donahue A, Braun D, Rini B, Powles T, Haanen J, et al.
Cancer Discov
. 2024 Feb;
14(3):406-423.
PMID: 38385846
Significance: Our findings provide novel insights into the different immunomodulatory mechanisms governing responses in patients treated with avelumab (PD-L1 inhibitor) + axitinib or sunitinib (both VEGF inhibitors), highlighting the contribution...
2.
Motzer R, Robbins P, Powles T, Albiges L, Haanen J, Larkin J, et al.
Nat Med
. 2020 Sep;
26(11):1733-1741.
PMID: 32895571
We report on molecular analyses of baseline tumor samples from the phase 3 JAVELIN Renal 101 trial (n = 886; NCT02684006 ), which demonstrated significantly prolonged progression-free survival (PFS) with...
3.
Donahue A, Abdool A, Gaur R, Wohlgemuth J, Yeh C
Leuk Res
. 2011 Jul;
35(11):1477-83.
PMID: 21764131
Current strategies for detecting chromosome abnormalities in MDS/AML include FISH or traditional cytogenetics. MLPA detects abnormalities in multiple loci simultaneously, with higher resolution and throughput. Peripheral blood from 50 healthy...
4.
Ma W, Kantarjian H, Zhang K, Zhang X, Wang X, Chen C, et al.
BMC Med Genet
. 2010 Nov;
11:163.
PMID: 21078205
Background: Myelodysplastic syndrome (MDS) may be induced by certain mutagenic environmental or chemotherapeutic toxins; however, the role of susceptibility genes remains unclear. The G/G genotype of the single-nucleotide polymorphism (SNP)...
5.
Abdool A, Donahue A, Wohlgemuth J, Yeh C
PLoS One
. 2010 Nov;
5(10):e15407.
PMID: 21049055
Current diagnostic screening strategies based on karyotyping or fluorescent in situ hybridization (FISH) for detection of chromosomal abnormalities in chronic lymphocytic leukemia (CLL) are laborious, time-consuming, costly, and have limitations...
6.
Ma W, Kantarjian H, Bekele B, Donahue A, Zhang X, Zhang Z, et al.
Clin Cancer Res
. 2009 May;
15(11):3820-6.
PMID: 19458051
Purpose: Cytogenetic abnormalities are currently the most important predictors of response and clinical outcome for patients with acute myeloid leukemia (AML) or advanced-stage myelodysplastic syndrome (MDS). Because clinical outcomes vary...
7.
Albitar M, Potts S, Giles F, OBrien S, Jilani I, Donahue A, et al.
Exp Hematol
. 2009 May;
37(7):784-90.
PMID: 19422784
Objective: Response to chemotherapy is achieved in 60% to 70% of patients with acute myeloid leukemia. The ability to predict responders may help in stratifying patients and exploring different therapeutic...
8.
Ma W, Kantarjian H, Zhang X, Jilani I, Sheikholeslami M, Donahue A, et al.
Cancer Biomark
. 2009 Feb;
5(1):51-8.
PMID: 19242062
Roughly one-third of acute myeloid leukemia (AML) patients exhibit mutations in the nucleophosmin (NPM1) gene, and multiple studies have linked these mutations with a more favorable clinical outcome. We developed...
9.
Donahue A, Kharas M, Fruman D
Methods Enzymol
. 2007 Oct;
434:131-54.
PMID: 17954246
Phosphoinositide 3-kinase (PI3K) is a lipid kinase whose activation is crucial for many biological functions in multiple cell types. One research area of particular interest for basic biologists and drug...
10.
Donahue A, Fruman D
Eur J Immunol
. 2007 Aug;
37(10):2923-36.
PMID: 17724683
Phosphoinositide 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR), a downstream kinase, are both required for proliferation of splenic B cells. However, the functions of PI3K and mTOR in...